- Open
- 0.42
- High
- 0.42
- Low
- 0.34
- Close
- 0.34
- Change
- -0.06 (-14.75%)
- Volume
- 1,906,259
| 7 Jul 2026 | 16:15:17 | MED3000 (Eroxon®) European Patent Opposition |
| 30 Jun 2026 | 17:02:12 | Holding(s) in Company |
| 30 Jun 2026 | 07:00:07 | Highly positive data from WSD4000 studies |
| 29 Jun 2026 | 14:17:35 | Correction: Result of AGM |
| 29 Jun 2026 | 13:14:19 | Result of AGM |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 5 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 11 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Futura Medical plc develops and commercializes consumer health products focused on sexual health. The company’s lead product, Eroxon®, is a clinically proven topical gel for the treatment of erectile dysfunction, available over the counter in multiple markets including Europe and the USA. Futura is also developing WSD4000, a portfolio of topical gels aimed at addressing female sexual dysfunction. The company operates a hybrid business model that combines research and development with commercial partnerships to enhance market reach and sustainability. Futura is based in Guildford, United Kingdom, and targets global consumer healthcare markets.
| 7 Jul 2026 | 16:15:17 | MED3000 (Eroxon®) European Patent Opposition |
| 30 Jun 2026 | 17:02:12 | Holding(s) in Company |
| 30 Jun 2026 | 07:00:07 | Highly positive data from WSD4000 studies |
| 29 Jun 2026 | 14:17:35 | Correction: Result of AGM |
| 29 Jun 2026 | 13:14:19 | Result of AGM |
| 18 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 5 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 11 Jun 2024 | Annual Report and Accounts (to 2023-12-31) |
Futura Medical plc develops and commercializes consumer health products focused on sexual health. The company’s lead product, Eroxon®, is a clinically proven topical gel for the treatment of erectile dysfunction, available over the counter in multiple markets including Europe and the USA. Futura is also developing WSD4000, a portfolio of topical gels aimed at addressing female sexual dysfunction. The company operates a hybrid business model that combines research and development with commercial partnerships to enhance market reach and sustainability. Futura is based in Guildford, United Kingdom, and targets global consumer healthcare markets.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £61m | -0.3% | |
| £58m | -0.0% | |
| £26m | +0.6% | |
| £9m | +0.3% | |
FUMFutura Medical PLC | £2m | -1.0% |
| £1m | — |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £61m | -0.3% | |
| £58m | -0.0% | |
| £26m | +0.6% | |
| £9m | +0.3% | |
FUMFutura Medical PLC | £2m | -1.0% |
| £1m | — |
